Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Barclays PLC raised its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 418.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,222 shares of the specialty pharmaceutical company’s stock after acquiring an additional 54,257 shares during the period. Barclays PLC owned approximately 0.14% of KalVista Pharmaceuticals worth $778,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares in the last quarter. Intech Investment Management LLC acquired a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $126,000. SG Americas Securities LLC purchased a new stake in KalVista Pharmaceuticals in the third quarter valued at about $153,000. Quest Partners LLC acquired a new stake in KalVista Pharmaceuticals in the third quarter worth about $175,000. Finally, Evoke Wealth LLC acquired a new stake in KalVista Pharmaceuticals in the second quarter worth about $181,000.

KalVista Pharmaceuticals Trading Up 6.2 %

Shares of NASDAQ:KALV opened at $7.86 on Thursday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The company’s 50 day moving average is $9.25 and its 200 day moving average is $11.23. The company has a market cap of $388.43 million, a PE ratio of -2.16 and a beta of 0.86.

Analyst Upgrades and Downgrades

KALV has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Bank of America initiated coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, KalVista Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $25.00.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the transaction, the chief executive officer now directly owns 266,598 shares of the company’s stock, valued at $2,468,697.48. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,291 shares of company stock worth $304,086 over the last 90 days. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).